- $763.91m
- $427.75m
Annual balance sheet for Jade Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 167 | 129 | 122 | 78.6 | 336 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 174 | 131 | 124 | 80.1 | 349 |
| Net Property, Plant And Equipment | 0.728 | 1.25 | 0.902 | 0.215 | 0.896 |
| Other Long Term Assets | |||||
| Total Assets | 175 | 135 | 127 | 80.3 | 350 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 2.55 | 7.78 | 17.6 | 3.83 | 16.5 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 2.94 | 8.56 | 18 | 3.9 | 17.3 |
| Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 172 | 127 | 109 | 76.4 | 333 |
| Total Liabilities & Shareholders' Equity | 175 | 135 | 127 | 80.3 | 350 |
| Total Common Shares Outstanding |